Precise base editing of pathogenic variants in primary human T cells with engineered cytidine deaminases.
CRISPR base editors convert one DNA base into another without inducing double-strand breaks, but bystander edits at nearby positions limit therapeutic use. We engineer a cytidine deaminase variant with a narrowed editing window and demonstrate single-base precision at clinically relevant loci in primary human T cells.
Overview ↗